Stocks and InvestingStocks and Investing
Tue, January 30, 2024
Mon, January 29, 2024
Fri, January 26, 2024

Matt Miksic Maintained (ABT) at Buy with Increased Target to $141 on, Jan 26th, 2024


Published on 2024-10-28 08:35:29 - WOPRAI, Matt Miksic
  Print publication without navigation


Matt Miksic of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $133 to $141 on, Jan 26th, 2024.

Matt has made no other calls on ABT in the last 4 months.



There are 5 other peers that have a rating on ABT. Out of the 5 peers that are also analyzing ABT, 1 agrees with Matt's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lewis of "Morgan Stanley" Maintained at Hold with Decreased Target to $107 on, Thursday, October 19th, 2023


These are the ratings of the 4 analyists that currently disagree with Matt


  • Jayson Bedford of "Raymond James" Maintained at Buy with Increased Target to $127 on, Thursday, January 25th, 2024
  • Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Increased Target to $126 on, Thursday, January 25th, 2024
  • Shagun Singh of "RBC Capital" Reiterated at Buy and Held Target at $128 on, Thursday, January 25th, 2024
  • Lawrence Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $121 on, Wednesday, December 13th, 2023